Status:
COMPLETED
Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
Lead Sponsor:
Corewell Health South
Conditions:
Atrial Fibrillation
Atrial Flutter
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Depa...
Eligibility Criteria
Inclusion
- Heart rate \>125
- Systolic BP\>110
- Atrial Fibrillation/Flutter confirmed on ECG.
- Meets observation unit requirements (performs certain ADL's (acts of daily living)
- Age\>18.
Exclusion
- Wolf-Parkinson-White syndrome
- ST Elevation Myocardial Infarction
- Pregnant
- Clinical diagnosis of Sepsis,
- Decompensated HF
- allergy to Diltiazem
- provider discretion
- clinical need for cardioversion
Key Trial Info
Start Date :
June 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2023
Estimated Enrollment :
444 Patients enrolled
Trial Details
Trial ID
NCT05391893
Start Date
June 19 2020
End Date
April 1 2023
Last Update
December 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Matthew Hysell
Saint Joseph, Michigan, United States, 49085